Inovotion is a breakthrough in vivo platform without animal experimentation-3Rs with multiple value creation applications in Drug Discovery and Personalize Medicine.

Inovotion’s Drug Discovery solution, for anticancer drugs including Immuno-Oncology, deliver faster results, higher sensitivity, strong reliability, and very large cost savings. By eliminating low-value molecules, Inovotion accelerates the drug discovery process and significantly reduces its costs and the animal use. Inovotion has carried out over 650 in vivo studies for over 130 customers in Pharma and Biotech in Europe, USA, and Asia.

Inovotion develops new applications for Personalized Medicine, based on a unique assay to grow tumor avatars derived from patients’ Organoids, Biopsies or Circulating Tumor Cells (CTCs).
Inovotion has so far self-financed the development of its multi-function platform though a successful CRO business (over 45% growth in 2023).
Inovotion is now seeking a powerful partner to accelerate its development and disseminate throughout the Biopharma industry in USA and Europe.

Inovotion’s Drug Discovery solution is tailored for anticancer drugs, including those in Immuno-Oncology. It provides quicker outcomes, enhanced sensitivity, exceptional reliability, and substantial cost reductions compared to traditional models. By weeding out molecules of low potential, Inovotion expedites the drug discovery journey, drastically cutting down on expenses and the need for animal testing.

Their next generation of in vivo efficacy and toxicity tests:
#EFFICACY of oncology or immuno-oncology drugs
#EARLY TOXICITY assays
#TARGET VALIDATION in oncology
#MULTI-CANCER SCREENING to (re)position
#MECHANISM OF ACTION (angiogenesis, fibrosis, immune cell infiltration, transciptomic, PK,…)
INOVOTION has also developed news assay dedicated to the evaluation of biomaterial.

–  Therapeutic areas: Oncology, Immuno-Oncology

–  Based in: Gières (FRANCE)

–  Employees: 11 – 50

–  Created in: 2015